

***Remarks***

In accordance with 37 C.F.R. § 1.821(g), this submission includes no new matter. The specification has been amended to update the status of priority information, and to direct the entry of the corrected Sequence Listing at the end of the application. The sequence listing was amended to reflect that the proper designation for the single letter amino acid "B" is alpha-amino butyric acid and not Asx. Support for this amendment can be found, *inter alia*, on page 60, lines 1-3.


In accordance with 37 C.F.R. § 1.821(f), the paper copy of the Sequence Listing and the computer readable copy of the Sequence Listing submitted herewith in the above application are the same.

***Summary***

It is respectfully believed that this application is now in condition for examination. Early notice to this effect is respectfully requested.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Paul A. Calvo  
Agent for Applicants  
Registration No. 57,913

Date: 1/11/2006  
1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600